Last reviewed · How we verify
NCT03709186
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
trial in Invasive Breast Cancer in 100 participants. Completed in 1 January 2021.
1 September 2020
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 October 2018 |
| Primary completion | 1 September 2020 |
| Estimated completion | 1 January 2021 |
| Sites | 1 location across Canada |
Conditions studied
- Invasive Breast Cancer — all drugs for Invasive Breast Cancer →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, any sex, with Invasive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of the study is to identify radiomic features as biomarkers of metastatic progression following primary therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review.
Reginelli A, Nardone V, Giacobbe G, Belfiore MP, et al · · 2021 · cited 39× · PMID 34679494 · DOI 10.3390/diagnostics11101796
Verify or expand the search:
- PubMed search for NCT03709186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Invasive Breast Cancer
Currently open trials in the same condition.
- NCT07421479 — Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01) · active not recruiting
- NCT06677944 — Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer · Phase 2 · recruiting
- NCT05795101 — TRUDI: TDXD+Durva in HER2+/Low IBC · Phase 2 · recruiting
- NCT05383196 — Onvansertib + Paclitaxel In TNBC · Phase 1, PHASE2 · active not recruiting
- NCT05412225 — A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction · Phase 1 · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03709186 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 11 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03709186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing